2023-03-13 07:23:51 ET
- BioRestorative Therapies ( NASDAQ: BRTX ) signed an agreement with Bruder Consulting & Venture Group for help in seeking FDA approval to expand the clinical application for BRTX-100.
- The cell therapy BRTX-100 is being evaluated in connection with a phase 2 trial in chronic lumbar disc disease (cLDD) — a disorder that causes lower back and leg pain.
- In June 2022, the company said the first patient was enrolled in the phase 2 study, which will enroll up to 99 patients at up to 15 sites in the U.S.
- The company noted that the advisory firm has been engaged to expand BRTX-100 clinical indication pipeline.
- "Finding the right partner such as BCVG is very meaningful to BioRestorative as they bring a tremendous amount of domain expertise in managing the regulatory pathway for cellular therapies. Additionally, we have the opportunity to leverage this musculoskeletal platform across other indications within the body," said BioRestorative CEO Lance Alstodt.
For further details see:
BioRestorative engages advisory firm for clinical application of cell therapy BRTX-100